Standardization of a Platform of Preclinical Models Derived From NSCLC Patients

Characterize and trace innovative nutraceuticals based on microencapsulated resveratrol and Cynara cardunculus extract, using preclinical models such as organotypic tissue slices and tumoroids created from tumor fragments derived from patients with non-small cell lung cancer. This will enable the development of combination therapies to increase the efficacy of immunotherapy in NSCLC and reduce side effects that lead to treatment discontinuation. The market implementation of these products may offer unique advantages, including increased clinical efficacy, improved tolerability of immune checkpoint inhibitors, reduced healthcare costs, improved quality of life for patients and their families, traceability of naturally derived products, and environmental sustainability.

Inclusion criteria: * Patients over 18 years of age; * Patients diagnosed with resectable NSCLC who will undergo curative surgery; * Patients who give written informed consent (study participation and data processing). Exclusion criteria: * Previous malignancies; * Previous systemic treatments.